Birzeit Pharmaceuticals (BPC) Stock Overview
Operates as a pharmaceutical manufacturing company in the Palestinian Authority. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
BPC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Birzeit Pharmaceuticals Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.70 |
| 52 Week High | US$4.45 |
| 52 Week Low | US$3.55 |
| Beta | 0 |
| 1 Month Change | -0.80% |
| 3 Month Change | -3.90% |
| 1 Year Change | -2.12% |
| 3 Year Change | -10.41% |
| 5 Year Change | 40.95% |
| Change since IPO | 190.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| BPC | PS Pharmaceuticals | PS Market | |
|---|---|---|---|
| 7D | -0.8% | -0.9% | -0.1% |
| 1Y | -2.1% | 1.5% | 8.7% |
Return vs Industry: BPC underperformed the PS Pharmaceuticals industry which returned 1% over the past year.
Return vs Market: BPC underperformed the PS Market which returned 8.7% over the past year.
Price Volatility
| BPC volatility | |
|---|---|
| BPC Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in PS Market | 5.6% |
| 10% least volatile stocks in PS Market | 2.4% |
Stable Share Price: BPC has not had significant price volatility in the past 3 months compared to the PS market.
Volatility Over Time: BPC's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1973 | 372 | Firas Kathem Nasereddin | bpc.ps |
Birzeit Pharmaceuticals Company operates as a pharmaceutical manufacturing company in the Palestinian Authority. The company offers OTC products for alimentary system cardiovascular system, central nervous system, musculo-skeletal system, endocrine, genito-urinary system, diabetes, obstetrics and gynecology infections, affecting nutrition and metabolism, respiratory system, ophthalmic drugs, dermatological preparations, and dietary supplements, as well as ear, nose, and oropharynx therapeutic areas. It serves the Ministry of Health, healthcare organizations and programs, and consumers through pharmacies and doctors.
Birzeit Pharmaceuticals Company Fundamentals Summary
| BPC fundamental statistics | |
|---|---|
| Market cap | US$143.43m |
| Earnings (TTM) | US$12.59m |
| Revenue (TTM) | US$49.21m |
Is BPC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BPC income statement (TTM) | |
|---|---|
| Revenue | US$49.21m |
| Cost of Revenue | US$30.94m |
| Gross Profit | US$18.27m |
| Other Expenses | US$5.68m |
| Earnings | US$12.59m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.32 |
| Gross Margin | 37.12% |
| Net Profit Margin | 25.58% |
| Debt/Equity Ratio | 1.0% |
How did BPC perform over the long term?
See historical performance and comparisonDividends
Does BPC pay a reliable dividends?
See BPC dividend history and benchmarks| Birzeit Pharmaceuticals dividend dates | |
|---|---|
| Ex Dividend Date | May 06 2026 |
| Dividend Pay Date | Jul 15 2026 |
| Days until Ex dividend | 67 days |
| Days until Dividend pay date | 3 days |
Does BPC pay a reliable dividends?
See BPC dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/11 15:54 |
| End of Day Share Price | 2026/07/09 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Birzeit Pharmaceuticals Company is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.